fda grants fast track designation to xylocor therapeutics lead candidate xc  business wire fda grants fast track designation to xylocor therapeutics lead candidate xc may    am eastern daylight time newtown square pabusiness wirexylocor therapeutics inc a privately held biotech company today announced that the us food and drug administration fda has granted fast track designation to its lead product candidate xc advegfalla a cardiovascular angiogenic gene therapy xc is a onetime treatment being investigated for improving exercise tolerance in patients who have chronic angina that is refractory to standard medical therapy and not amenable to conventional revascularization procedures such as coronary artery bypass surgery and percutaneous coronary intervention and stents “achieving fast track status validates the need for xc which has the potential to be a unique treatment for this serious condition with high unmet need  chronic refractory angina” said al gianchetti president and chief executive officer of xylocor “this designation is supported by strong scientific evidence for xc and clinical validation of this mechanism of action in refractory angina this important designation is intended to contribute to an expedited development and regulatory review process which can get the drug sooner to patients who can benefit from it” the fda fast track designation is designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and that demonstrate the potential to address an unmet medical need xc is a novel gene therapy that promotes angiogenesis the formation of new vessels that can provide arterial blood flow to myocardial regions with inadequate blood supply enhancing myocardial blood flow with therapeutic angiogenesis is intended to relieve myocardial ischemia improve regional and global left ventricular performance alleviate angina symptoms and disability and potentially improve prognosis “there are many patients in the united states with refractory angina and there are no available treatment options” said magnus ohman professor of medicine the kent and siri rawson director duke program for advanced coronary disease duke university school of medicine “these patients have significant limitations in terms of their daily activities because of the chest pain associated with their ischemic disease and xc could be an important new option for them” an ind for xc is open with the fda and xylocor intends to commence clinical trials upon funding about xylocor xylocor therapeutics is a private biopharmaceutical company developing novel gene therapy for people with unmet medical need from advanced coronary artery disease xylocor is focused on developing its lead product xc for patients with refractory angina with no treatment options and its secondary product xc for patients with cardiac tissue damage from heart attacks xylocor was founded by dr ronald crystal and dr todd rosengart who both sit on xylocor’s advisory board dr crystal is the bruce webster professor and chairman department of genetic medicine weill cornell medicine and director of the belfer gene therapy core facility dr rosengart is professor and chairman debakey bard chair of surgery michael e debakey department of surgery baylor college of medicine xylocor has a licensing agreement with cornell university granting the company worldwide rights to develop manufacture and commercialize xc with a strong scientific foundation compelling preclinical and clinical evidence and an experienced team xylocor is poised for success and to help patients lead better healthier lives for more information visit wwwxylocorcom contacts xylocor therapeutics incal gianchettipresident and chief executive officerinfoxylocorcomormediasam brown incmike beyer mikebeyersambrowncom contacts xylocor therapeutics incal gianchettipresident and chief executive officerinfoxylocorcomormediasam brown incmike beyer mikebeyersambrowncom search advanced news search advanced news search log in sign up xylocor therapeutics inc private company information  bloomberg july    am et biotechnology company overview of xylocor therapeutics inc snapshot people company overview xylocor therapeutics inc develops gene therapy for cardiovascular diseases the company was incorporated in  and is based in newtown square pennsylvania  longview lanenewtown square pa united statesfounded in  phone  wwwxylocorcom key executives for xylocor therapeutics inc mr albert gianchetti president chief executive officer and director compensation as of fiscal year  xylocor therapeutics inc key developments xylocor therapeutics inc presents at boston ceo conference may  am may   xylocor therapeutics inc presents at boston ceo conference may  am venue four season boston  boylston street boston ma  united states speakers albert gianchetti president chief executive officer and director xylocor therapeutics inc presents at th annual conference biotech showcase jan nov   xylocor therapeutics inc presents at th annual conference biotech showcase jan  venue hilton san francisco union square  ofarrell street san francisco ca  united states xylocor therapeutics inc presents at th annual biotech showcase investor conference  jan  pm jan   xylocor therapeutics inc presents at th annual biotech showcase investor conference  jan  pm venue parc  san francisco  cyril magnin street san francisco ca  united states similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target private placement november    request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact xylocor therapeutics inc please visit wwwxylocorcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close xylocor therapeutics inc company profile bioportfolio biotech healthcare and medical resources advertisement topics all topics biotechnology biotech business biotech products cancer cardiovascular dermatology drug discovery endocrinology gastroenterology immunology infectious diseases mental health neurology obstetrics orthopedics public health respiratory rheumatology urology  track topics on twitter track topics that are important to you printed from bioportfoliocom xylocor therapeutics inc company profile  edt th july   bioportfolio xylocor therapeutics is a private biopharmaceutical company developing novel gene therapy for people with unmet medical need from advanced coronary artery diseaseâ xylocor is focused on developing its lead product xc for patients with refractory angina with no treatment options and its secondary product xc for patients with cardiac tissue damage from heart attacks xylocor was founded by dr ronald crystal and dr todd rosengart who both sit on xylocorâs advisory board dr crystal is the bruce webster professor and chairman department of genetic medicine weill cornell medicine and director of the belfer gene therapy core facilityâ dr rosengart is professor and chairman debakey bard chair of surgery michael e debakey department of surgery baylor college of medicineâ xylocor has a licensing agreement with cornell university granting the company worldwide rights to develop manufacture and commercialize xc with a strong scientific foundation compelling preclinical and clinical evidence and an experienced team xylocor is poised for success and to help patients lead better healthier lives for more information visit wwwxylocorcom news articles  associated news articles listed on bioportfolio xylocors chronic angina drug gets fda fasttrack status xylocor therapeutics drug candidate xc has been granted fasttrack designation by the fda as a treatment to improve exerc more  xylocor’s cardiovascular gene therapy gets fda fast track designation the us food and drug administration fda has granted fast track designation to xylocor therapeutics’ lead product candidate xc advegfalla a cardiovascular angiogenic gene therapy fda grants fast track designation to xylocor therapeutics lead candidate xc xylocor therapeutics inc a privately held biotech company today announced that the us food and drug administration fda has granted fast track designation to its lead produ summit therapeutics plc smmt and orexigen therapeutics orex head to head review summit therapeutics plc and orexigen therapeutics are both smallcap medical companies but which is the better business we will compare the two companies based on the strength of their dividends in crispr therapeutics casebia therapeutics partner with stridebio crispr therapeutics a biopharmaceutical company focused on creating transformative genebased medicines for serious diseases and casebia therapeutics a jointventure established by crispr therapeut rana therapeutics relaunches as translate bio to advance rna therapeutics tuesday june th  at am utc — company expands executive leadership team with key appointments in early  — cambridge mass–business wire– rana therapeutics tod crispr therapeutics and neon therapeutics enter research collaboration cambridge mass and basel switzerland july   globe newswire — crispr therapeutics nasdaqcrsp a biopharmaceutical company focused on creating transformative genebased medicines mas this week bioverativ therapeutics horizon pharma bioverativ therapeutics has reached an agreement to acquire clinicalstage biotechnology company true north therapeutics drugs and medications  associated drugs and medications listed on bioportfolio aldex pernix therapeutics llc aldex gs™ tablets aldex pernix therapeutics llc aldex gs dmtablets proden rx zila therapeutics inc proden rx proden rx zila therapeutics inc proden rx proden rx zila therapeutics inc proden rx pubmed articles  associated pubmed articles listed on bioportfolio correction to journal of ocular pharmacology and therapeutics  correction to journal of ocular pharmacology and therapeutics  robert burton nussenblatt md mph  physicianscientist leading ophthalmologist and exemplary teacher response to aslankurt et al re safety profile of stromal hydration of clear corneal incisions with cefuroxime in the mouse model an alternative to topical dosing to deliver drugs to target tissues clinical trials  associated clinical trials listed on bioportfolio impact of ibis on patients with advanced copd the purpose of this research is to determine if ibis™ a digital therapeutics solution developed by senscio systems reduces the emergency room visits and hospitalizations of patients wi hdl acute lipid optimization in homozygous familial hypercholesterolemia assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated hdlpreβ enriched plasma following use of hdl therapeutics pds™ system ontogenesis of the pglycoprotein in human lymphocytes influence of hiv and antiretroviral therapeutics the pglycoprotein pgp is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act a trial to find safe and active doses of an investigational drug cx for patients with solid tumors or lymphomas the purpose of this firstinhuman study of cx is to characterize the safety tolerability pharmacokinetics pk pharmacodynamics pd and antitumor activity of cx administered i a study of bbi in combination with selected anticancer therapeutics in adult patients with advanced cancer this is an open label multicenter phase  study of bbi administered in combination with selected anticancer therapeutics in adult patients with advanced cancer the goal of the st companies  associated companies listed on bioportfolio xylocor therapeutics inc xylocor therapeutics is a private biopharmaceutical company developing novel gene therapy for people with unmet medical need from advanced coronary artery diseaseâ xylocor is f aeris therapeutics aeris therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva altair therapeutics inc based in san diego altair therapeutics inc is a privatelyheld biopharmaceutical company developing novel therapeutics to treat human respiratory diseases altair therap vaxiion therapeutics inc vaxiion is dedicated to the design and development of intelligent drugdelivery technologies with special emphasis on targeted oncology therapeutics vaxiion therapeutics was spun click therapeutics inc click therapeutics inc engineers validates and commercializes digital therapeuticsâ¢ solutions to benefit people with unmet medical needs through cognitive and neurobehavi more information about xylocor therapeutics inc on bioportfolio we have published hundreds of xylocor therapeutics inc news stories on bioportfolio along with dozens of xylocor therapeutics inc clinical trials and pubmed articles about xylocor therapeutics inc for you to read in addition to the medical data news and clinical trials bioportfolio also has a large collection of xylocor therapeutics inc companies in our database you can also find out about relevant xylocor therapeutics inc drugs and medications on this site too quick linksadvanced search  login  subscribe  rss quick search advertisement   relevant topics biological therapy biological therapy involves the use of living organisms substances derived from living organisms or laboratoryproduced versions of such substances to treat disease some biological therapies for cancer use vaccines or bacteria to stimulate the bodyrs acute coronary syndromes acs acute coronary syndromes acs is an umbrella term for situations where the blood supplied to the heart muscle is suddenly blocked treatment for acute coronary syndrome includes medicines and a procedure known as angioplasty during which doctors inflat corporate database quicklinks search corporate database latest corporate records biotech companies by location popular company records recent company searches add or control your corporate profile searches linking to this company recordxylocor locationxylocor therapeutics address bioportfolio limited about us contact us social media twitter  accounts twitter google linkedin publish content publish publish your press release advertise agreements agreements medical disclaimer privacy tools mybioportfolio rss help faqs sitemaps xml sitemap this site complies with the honcode standard for trustworthy health information verify here the information provided by bioportfoliocom is not a substitute for professional medical advice diagnosis or treatment the bioportfolio site is sponsored bioportfolio limited with offices at stafford house  prince of wales road dorchester dt pw england if you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “fair use” and legitimately infringes on your or your clients copyright we may be contacted concerning copyright matters at prioritybioportfoliocom all rights reserved all other trademarks recognized copyright   bioportfolio limited site developed by alacrify ltd fda grants fast track designation to xylocor therapeutics lead candidate xc employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       fda grants fast track designation to xylocor therapeutics lead candidate xc tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs newtown square pabusiness wirexylocor therapeutics inc a privately held biotech company today announced that the us food and drug administration fda has granted fast track designation to its lead product candidate xc advegfalla a cardiovascular angiogenic gene therapy xc is a onetime treatment being investigated for improving exercise tolerance in patients who have chronic angina that is refractory to standard medical therapy and not amenable to conventional revascularization procedures such as coronary artery bypass surgery and percutaneous coronary intervention and stents “there are many patients in the united states with refractory angina and there are no available treatment options” “achieving fast track status validates the need for xc which has the potential to be a unique treatment for this serious condition with high unmet need  chronic refractory angina” said al gianchetti president and chief executive officer of xylocor “this designation is supported by strong scientific evidence for xc and clinical validation of this mechanism of action in refractory angina this important designation is intended to contribute to an expedited development and regulatory review process which can get the drug sooner to patients who can benefit from it” the fda fast track designation is designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and that demonstrate the potential to address an unmet medical need xc is a novel gene therapy that promotes angiogenesis the formation of new vessels that can provide arterial blood flow to myocardial regions with inadequate blood supply enhancing myocardial blood flow with therapeutic angiogenesis is intended to relieve myocardial ischemia improve regional and global left ventricular performance alleviate angina symptoms and disability and potentially improve prognosis “there are many patients in the united states with refractory angina and there are no available treatment options” said magnus ohman professor of medicine the kent and siri rawson director duke program for advanced coronary disease duke university school of medicine “these patients have significant limitations in terms of their daily activities because of the chest pain associated with their ischemic disease and xc could be an important new option for them” an ind for xc is open with the fda and xylocor intends to commence clinical trials upon funding about xylocor xylocor therapeutics is a private biopharmaceutical company developing novel gene therapy for people with unmet medical need from advanced coronary artery disease xylocor is focused on developing its lead product xc for patients with refractory angina with no treatment options and its secondary product xc for patients with cardiac tissue damage from heart attacks xylocor was founded by dr ronald crystal and dr todd rosengart who both sit on xylocor’s advisory board dr crystal is the bruce webster professor and chairman department of genetic medicine weill cornell medicine and director of the belfer gene therapy core facility dr rosengart is professor and chairman debakey bard chair of surgery michael e debakey department of surgery baylor college of medicine xylocor has a licensing agreement with cornell university granting the company worldwide rights to develop manufacture and commercialize xc with a strong scientific foundation compelling preclinical and clinical evidence and an experienced team xylocor is poised for success and to help patients lead better healthier lives for more information visit wwwxylocorcom xylocor therapeutics incal gianchettipresident and chief executive officerinfoxylocorcomormediasam brown incmike beyer mikebeyersambrowncom read at biospacecom related news mitsubishi tanabe wins fda approval for radicava the first new als drug in  years yet another measles outbreak traces directly to antivaccine autism panic the fda spurns reports fox news is the only show allowed at hq blockchain the missing link between genomics and privacy will therapeuticsmd txmds yuvvexy pass the fda muster novo nordisk as nvo needs new blood despite q relief fastgrowing intarcia awaits crucial fda decision in new boston hq can zapping your neck help you quickly learn a foreign language johns hopkins university reveals senate committee approves scott gottlieb for top fda job trumps new hhs appointee yoest thinks abortion raises breast cancer risk but wheres the evidence please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • food and drug administration fda   • clinical  research                 xylocor therapeutics inc  company profile  biocentury publications archives bciq conferences version  free trial  subscribe sign in english   한국어 biocentury menu home  publications  publications home  biocentury bc innovations bc extra bc week in review current issues archives  archives home  basic search advanced search back issues bciq  bciq home  overview pipeline analyst financial analyst company analyst deal analyst conferences  conferences home  newsmakers bio€quity europe future leaders china healthcare summit other industry events elearning  elearning home  videos white papers follow us bciq  company profile bciq overview      settings      support biocentury print this       xylocor therapeutics inc print preview export bookmark share with colleague general information  location newtown square pa  region pennsylvania  delaware valley  country us  business category genecell therapy cardiovascular  year founded   website httpxylocorcom  lead product status ind  archive items are loading  financial information  financing summary  financing details  earnings summary  stocks annual chart  pipeline information  pipeline summary  pipeline details  deals information  deals summary  deals details about biocentury company overview management editorial  research contact contact us advertising  sponsorship career opportunities support forgot password customer service reprints faqs products  solutions products overview publications archives bciq conferences elearning rss feeds legal user agreement terms of use privacy policy your california privacy rights use of images follow us what is biocentury biocentury employs a fully integrated multimedia platform — including publications video online data solutions and conferences — to provide its audience with authoritative and uptodate intelligence about corporate strategy partnering emerging technology clinical data public policy and the financial markets sign in free trial   biocentury inc all rights reserved    terms  conditions  privacy policy set email alert dummy xylocor therapeutics inc company profile  financial information competitors and executivescategoriescitiessign infind companies  xylocor therapeutics incthis is a community generated profile and may be incompletesuggest editsxxylocor therapeutics inclocationnewtown square parevenueâtotal fundingkfoundedemployeesstageprivatecompany websitexylocorcomlinkedinâxylocor therapeutics is a developmentstage biotechnology company dedicated to developing firstinclass gene therapies for patients with unmet medical need in cardiovascular diseasexylocor therapeutics incs private funding roundsk totaldateamountinvestorsnov kunknownwant to view and download all of xylocor therapeutics incs funding roundsview financial datarecent news from xylocor therapeutics incstart trial to view recent news about xylocor therapeutics increquest trialbusiness data in your workflowsave time and work smarter with fresh data on companies leads and contactslearn about datafox apis and data th street san francisco ca   infodatafoxcomlinkedintwitterdatafoxproductwho benefitscustomerscompanybloglearn moreaccountbased marketingsales prospecting tipssales operations strategyfastestgrowing tech companies by regiontoursalesforce integrationslack integrationchrome extensiondatafox apisupportemail ushelp centerprivacy policyterms of service news  skip to content facebook twitter google plus linkedin youtube news fda grants fast track designation to xylocor therapeutics lead candidate xc  newtown square pa may   —  xylocor therapeutics inc a privately held biotech company today announced that the us food and drug administration fda has granted fast track designation to its lead product candidate xc advegfalla a cardiovascular angiogenic gene therapy xc is a onetime treatment being investigated for improving exercise tolerance in patients who have chronic angina that is refractory to standard medical therapy and not amenable to conventional revascularization procedures such as coronary artery bypass surgery and percutaneous coronary intervention and stents    “achieving fast track status validates the need for xc which has the potential to be a unique treatment for this serious condition with high unmet need – chronic refractory angina” said al gianchetti president and chief executive officer of xylocor “this designation is supported by strong scientific evidence for xc and clinical validation of this mechanism of action in refractory angina this important designation is intended to contribute to an expedited development and regulatory review process which can get the drug sooner to patients who can benefit from it”   the fda fast track designation is designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and that demonstrate the potential to address an unmet medical need   xc is a novel gene therapy that promotes angiogenesis the formation of new vessels that can provide arterial blood flow to myocardial regions with inadequate blood supply enhancing myocardial blood flow with therapeutic angiogenesis is intended to relieve myocardial ischemia improve regional and global left ventricular performance alleviate angina symptoms and disability and potentially improve prognosis     “there are many patients in the united states with refractory angina and there are no available treatment options” said magnus ohman professor of medicine the kent and siri rawson director duke program for advanced coronary disease duke university school of medicine “these patients have significant limitations in terms of their daily activities because of the chest pain associated with their ischemic disease and xc could be an important new option for them”   an ind for xc is open with the fda and xylocor intends to commence clinical trials upon funding     about xylocor   xylocor therapeutics is a private biopharmaceutical company developing novel gene therapy for people with unmet medical need from advanced coronary artery disease xylocor is focused on developing its lead product xc for patients with refractory angina with no treatment options and its secondary product xc for patients with cardiac tissue damage from heart attacks xylocor was founded by dr ronald crystal and dr todd rosengart who both sit on xylocor’s advisory board dr crystal is the bruce webster professor and chairman department of genetic medicine weill cornell medicine and director of the belfer gene therapy core facility dr rosengart is professor and chairman debakey bard chair of surgery michael e debakey department of surgery baylor college of medicine xylocor has a licensing agreement with cornell university granting the company worldwide rights to develop manufacture and commercialize xc with a strong scientific foundation compelling preclinical and clinical evidence and an experienced team xylocor is poised for success and to help patients lead better healthier lives for more information visit wwwxylocorcom     company contact al gianchetti president and chief executive officer infoxylocorcom   media contact mike beyer sam brown inc mikebeyersambrowncom    cornell’s research serves the region and beyond — companies › xylocor therapeutics inc skip to content cornell university office of the vice provost for research search cornell cornell’s research serves the region and beyond get listed criteria small business development next previous home companies beyond new york state xylocor therapeutics inc xylocor therapeutics inc biopharmaceuticals cardiovascular diseasegene therapy products xc xc xylocor therapeutics is a biopharmaceutical company developing gene therapy for people with advanced coronary artery disease  the company is focused on developing its lead product xc for patients with refractory angina with no treatment options its secondary product xc is for patients with cardiac tissue damage from heart attacks the company’s five year goals include successful clinical trials and the launch of xc cornell connection xylocor therapeutics was cofounded by a professor at weill cornell medicine its foundational technology is licensed from cornell university tags biopharmaceuticals cardiovascular diseasegene therapy mail print add wwwxylocorcom mailing xylocor therapeutics inc  longview lane newtown square pa  tel   algianchettixylocorcom presidentceo albert gianchetti founder ronald crystal founded  employees  xylocor therapeutics  skip to content facebook twitter google plus linkedin youtube xylocor therapeutics     fda grants fast track designation to xylocor therapeutics lead candidate xchomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballfda grants fast track designation to xylocor therapeutics lead candidate xcbusiness wiremay  reblogsharetweetsharenewtown square pabusiness wirexylocor therapeutics inc a privately held biotech company today announced that the us food and drug administration fda has granted fast track designation to its lead product candidate xc advegfalla a cardiovascular angiogenic gene therapy xc is a onetime treatment being investigated for improving exercise tolerance in patients who have chronic angina that is refractory to standard medical therapy and not amenable to conventional revascularization procedures such as coronary artery bypass surgery and percutaneous coronary intervention and stents“achieving fast track status validates the need for xc which has the potential to be a unique treatment for this serious condition with high unmet need  chronic refractory angina” said al gianchetti president and chief executive officer of xylocor “this designation is supported by strong scientific evidence for xc and clinical validation of this mechanism of action in refractory angina this important designation is intended to contribute to an expedited development and regulatory review process which can get the drug sooner to patients who can benefit from it”the fda fast track designation is designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and that demonstrate the potential to address an unmet medical needxc is a novel gene therapy that promotes angiogenesis the formation of new vessels that can provide arterial blood flow to myocardial regions with inadequate blood supply enhancing myocardial blood flow with therapeutic angiogenesis is intended to relieve myocardial ischemia improve regional and global left ventricular performance alleviate angina symptoms and disability and potentially improve prognosis“there are many patients in the united states with refractory angina and there are no available treatment options” said magnus ohman professor of medicine the kent and siri rawson director duke program for advanced coronary disease duke university school of medicine “these patients have significant limitations in terms of their daily activities because of the chest pain associated with their ischemic disease and xc could be an important new option for them”an ind for xc is open with the fda and xylocor intends to commence clinical trials upon fundingabout xylocorxylocor therapeutics is a private biopharmaceutical company developing novel gene therapy for people with unmet medical need from advanced coronary artery disease xylocor is focused on developing its lead product xc for patients with refractory angina with no treatment options and its secondary product xc for patients with cardiac tissue damage from heart attacks xylocor was founded by dr ronald crystal and dr todd rosengart who both sit on xylocor’s advisory board dr crystal is the bruce webster professor and chairman department of genetic medicine weill cornell medicine and director of the belfer gene therapy core facility dr rosengart is professor and chairman debakey bard chair of surgery michael e debakey department of surgery baylor college of medicine xylocor has a licensing agreement with cornell university granting the company worldwide rights to develop manufacture and commercialize xc with a strong scientific foundation compelling preclinical and clinical evidence and an experienced team xylocor is poised for success and to help patients lead better healthier lives for more information visit wwwxylocorcomview source version on businesswirecom httpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nexttobacco bondholders shrug off fda news while cigarette stocks are hit hardbloombergthis will be in everyones household by banyan hillsponsoredbritish american tobacco not surprised by fda move to cut nicotinereutersaltria shares plunge after fda releases road map to curb tobaccorelated deathscnbcamgen gets fast fda review for adding heart benefits to cholesterol drug labelreutersengineer finds pattern makes millions in stocksmoney morningsponsoredthe new fda plan for regulating cigarettes echoes a tobacco industry idea from the squartzanthony scaramuccis wife reportedly filed for divorce because he was hellbent on joining trumpbusiness insidermainstream model  holds promise  and peril  for teslaassociated pressdiscover it  out of  avg by k customersdiscover cardsponsoredthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderchevron and exxon mobil have a tough path ahead nyse traderyahoo finance videostocks mixed after heavy earnings weekcardiologist  foods you should quit immediatelygundry mdsponsoredthe real reason overseas manufacturing is coming to americayahoo financehere are the us targets north korea most likely wants to nukebusiness insiderstruggling to govern trump faces growing republican uneasestuart actually this is the best our country can do right now if the republicans accomplished anything it would be tax cuts for the wealthy cuts to medicaid medicare and social security removal of all banking regulations and environmental protections and on and on get rid of these traitors in  so our country can be great againjoin the conversation  k